Molecular insight into the expression level of an immunosuppression gene, VTCN1, and its regulatory factors in breast cancer patients and non-cancerous samples with a higher level of IgE

Abstract

IgE levels increase in some cancer types due to treatment methods also autoimmune diseases can emerge and lead to worsening of the cancer. Finding a factor based on the reduction in IgE levels found in cancer can act as a determinant in providing the early diagnosis of the disease in individuals with high IgE levels in their blood. Accordingly, in the present study, the effort was made to select a gene associated with breast cancer and high IgE levels through available databases to evaluate the gene expression and the associated lncRNA and polymorphism at the binding site of a miRNA with a gene. In this study, the expression of the VTCN1 gene and the associated lncRNA called NORAD (Non-Coding RNA Activated by DNA Damage), selected through bioinformatics methods and relevant databases were assessed in breast cancer tissue samples along with the blood samples of individuals with high IgE levels, employing the real-time PCR method. Lastly, NORAD’s protein interactions and the relevant signaling pathways were further investigated via bioinformatics tools. The results indicated that the expression of VTCN1 genes increased significantly (P < 0.05), whereas NORAD increased insignificantly (P > 0.05) in both breast cancer and high IgE level samples. The prevalence of GG genotype in polymorphism rs10754339 was similarly high in both categories of samples. Bioinformatic analyses also demonstrated NORAD's association with proteins involved in immunity pathways. This study suggests the VTCN1 and NORAD genes as convenient markers for monitoring breast cancer in people with high IgE levels, as well as employing them in the research regarding the autoimmune diseases in individuals with a breast cancer diagnosis.

Evaluation of BHMT2 Gene Expression and its Expression Factor Regulating LNC00922 LNCRNA with rs10944 Genotype Determination in Patients with Breast Cancer

“…Another study revealed the possible regulatory role of LINC00520 on the ESR2 expression level in BC samples (Ezzati et al, 2022). Also, another study revealed that lncRNA NORAD regulates the expression level of VTCN1 in BC (Rezvani Sichani et al, 2023). Based on the study of Barani et al at 2022, LINC01215 could regulate the expression level of THBS2 in ECM receptor signaling pathway among gastric cancer patients (Barani et al, 2022).…”

LINC1521 and miR-3679-5p modulate cellular response to chemical stress in breast cancer patients through regulation of XBP1 expression as a potential diagnostic biomarker

“…Our previous studies revealed the novel functions of lncRNAs in different cancer types. Based on the study of Rezvani Sichani et al, lncRNA NORAD regulates the expression level of VTCN1 in the BC samples (Rezvani et al, 2023).Barani et al revealed that lncRNA LINC01215 modulates ECM receptor signaling pathway through the regulation of THBS2 expression level in GC samples (Barani et al, 2022). LINC00520 also regulates the expression of ESR2 mRNA in BC samples as a potential diagnostic biomarker (Ezzati et al, 2022).…”

RGS2-related non-coding interaction network modulates the NF-Kappa B signaling pathway in MS patients: a systems biology investigation

“…It is noteworthy that certain lncRNAs have been identi ed as being dysregulated in peripheral blood mononuclear cells among individuals with MS, indicating their potential involvement in the pathogenesis of the disease (20,21). Our previous studies mentioned the potential biological roles of different lncRNAs in immune-related diseases, including different cancer types, including breast cancer (22)(23)(24)(25)(26), gastric cancer (27,28), and MS (29). Especially about MS, previous investigations mentioned novel regulatory lncRNAs with dysregulation in MS patients.…”